Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 3/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.42 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1861663 | 1.00 | KLK5 (0.45) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL1859578 | 0.91 | KLK5 (0.45) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL1859576 | 0.91 | KLK5 (0.45) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL1867178 | 0.91 | KLK5 (0.49) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL1861930 | 0.79 | KLK5 (0.43) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL1860829 | 0.77 | HPGD (0.42) | — | |
| SCHEMBL8082012 | 0.73 | ATM (0.56) | KLK5ATMACECTSSCTSL | |
| SCHEMBL7356966 | 0.73 | KLK5 (0.59) | KLK5ATMACECTSSCTSL | |
| SCHEMBL498943 | 0.72 | HTR2C (0.38) | KLK5ATMACECTSLKMT2A | |
| SCHEMBL3594100 | 0.71 | CTSK (0.46) | ATMCTSSCTSKKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | KLK5 256/4885ATM 2336/4885PSEN1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.